Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-26 3:41 pm Sale | 2026-03-13 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | VANGUARD GROUP INC | 0 0.000% | -5,804,912 (Position Closed) | Filing History |
| 2026-02-17 4:22 pm Purchase | 2025-12-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | TCG Crossover GP II LLC | 6,243,812 5.700% | 6,243,812 (New Position) | Filing History |
| 2026-02-12 09:09 am Sale | 2025-12-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | Adage Capital Management L.P. | 2,777,055 2.530% | -4,039,773 (-59.26%) | Filing History |
| 2026-02-05 1:16 pm Purchase | 2025-12-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | FMR LLC | 16,468,419 15.000% | 5,089,212 (+44.72%) | Filing History |
| 2026-01-30 1:27 pm Purchase | 2025-12-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | VANGUARD GROUP INC | 5,804,912 5.280% | 531,162 (+10.07%) | Filing History |
| 2026-01-21 12:30 pm Purchase | 2025-12-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | BlackRock Inc. BLK | 7,783,648 7.100% | 2,866,147 (+58.28%) | Filing History |
| 2025-11-17 5:39 pm Purchase | 2025-11-10 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | COMMODORE CAPITAL LP | 5,650,000 5.100% | 5,650,000 (New Position) | Filing History |
| 2025-11-14 4:10 pm Sale | 2025-09-30 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | Point72 Asset Management L.P. | 2,801,636 2.600% | -1,916,073 (-40.61%) | Filing History |
| 2025-11-14 4:00 pm Purchase | 2025-09-30 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | PERCEPTIVE ADVISORS LLC | 8,952,365 8.200% | 1,078,017 (+13.69%) | Filing History |
| 2025-11-13 09:05 am Sale | 2025-09-30 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | Adage Capital Management L.P. | 6,816,828 6.390% | -1,983,172 (-22.54%) | Filing History |
| 2025-10-30 2:37 pm Purchase | 2025-09-30 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | VANGUARD GROUP INC | 5,273,750 4.940% | 775,722 (+17.25%) | Filing History |
| 2025-10-07 3:49 pm Purchase | 2025-09-30 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | FMR LLC | 11,379,207 10.700% | 11,379,207 (New Position) | Filing History |
| 2025-08-12 09:07 am Purchase | 2025-06-30 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | Adage Capital Management L.P. | 8,800,000 9.870% | 3,102,395 (+54.45%) | Filing History |
| 2025-07-29 11:21 am Purchase | 2025-06-30 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | VANGUARD GROUP INC | 4,498,028 5.040% | 4,498,028 (New Position) | Filing History |
| 2025-07-17 7:44 pm Purchase | 2025-06-30 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | BlackRock Inc. BLK | 4,917,501 5.500% | 4,917,501 (New Position) | Filing History |
| 2025-06-25 5:24 pm Purchase | 2025-06-24 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | Point72 Asset Management L.P. | 4,717,709 5.300% | 3,669,366 (+350.02%) | Filing History |
| 2025-05-15 4:30 pm Purchase | 2025-03-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | PERCEPTIVE ADVISORS LLC | 7,874,348 8.800% | 1,100,000 (+16.24%) | Filing History |
| 2025-05-15 3:52 pm Sale | 2025-03-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | Point72 Asset Management L.P. | 1,048,343 1.200% | -3,771,990 (-78.25%) | Filing History |
| 2025-05-12 09:05 am Purchase | 2025-03-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | Adage Capital Management L.P. | 5,697,605 6.430% | 5,697,605 (New Position) | Filing History |
| 2025-02-14 4:30 pm Purchase | 2024-12-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX | Panacea Innovation Ltd | 2,200,000 2.600% | 2,200,000 (New Position) | Filing History |